Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Halozyme, with nine buys, three holds and one sell among 13 firms. The average 12-month price target is $91.20, though several firms recently raised targets as high as $115.
• Halozyme exceeded quarterly expectations, reporting $2.28 in EPS versus $1.79 expected and $481 million in revenue, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Institutional investors own 97.79% of the stock, with major firms including Norges Bank and William Blair initiating sizable positions. Meanwhile, insiders sold 52,477 shares worth approximately $3.67 million over the past 90 days.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $91.20.

A number of research firms recently weighed in on HALO. UBS Group reissued a "buy" rating and set a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley cut their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a report on Friday. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Friday. Finally, Leerink Partners upgraded Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the company from $83.00 to $110.00 in a research note on Friday.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares of the company's stock, valued at $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,477 shares of company stock valued at $3,667,643 in the last 90 days. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $124,031,000. Voloridge Investment Management LLC acquired a new position in Halozyme Therapeutics during the third quarter worth $77,587,000. Qube Research & Technologies Ltd bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $51,295,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Halozyme Therapeutics by 4,578.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company's stock valued at $78,086,000 after purchasing an additional 976,321 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $102.62 on Tuesday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $104.77. The firm has a fifty day moving average price of $77.17 and a two-hundred day moving average price of $71.70. The company has a market cap of $12.17 billion, a PE ratio of 30.63, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business's revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts expect that Halozyme Therapeutics will post 7.54 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source